文献速递胸部肿瘤支持与姑息治疗

肺癌与严重急性呼吸综合征冠状病毒2感染:确定需要研究的重要知识空白

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
PubMed 文献 · J Thorac Oncol · 2021-11-10

肺癌患者感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的风险更高,感染后住院率和病死率均较高。冠状病毒病2019(COVID-19)疫苗对肺癌患者安全有效,但部分患者抗体应答较差,可能需要加强接种。本文综述了肺癌合并COVID-19领域的关键知识空白,包括感染防护、治疗影响、抗体应答及病毒变异应对等。

要点

  • 肺癌患者感染SARS-CoV-2风险较对照高7倍以上,住院风险高3倍以上,病死率估计超过30%。
  • COVID-19疫苗对肺癌患者安全有效,但部分患者抗体应答较差,似需紧急加强接种。
  • 肺癌患者应继续抗肿瘤治疗并接种SARS-CoV-2疫苗。

核心结论

  • 基于现有数据,肺癌患者应继续其癌症治疗疗程并接种SARS-CoV-2疫苗。
  • 部分肺癌患者对疫苗接种的抗体应答较差,该脆弱亚组似需紧急加强接种。
  • 关于肺癌患者疫苗接种的抗体应答幅度、质量、持续时间及细胞免疫保护作用等许多问题仍未解答。

研究设计与样本

  • 本文为综述,识别肺癌与SARS-CoV-2感染领域的重要知识空白以供研究。

主要发现

  • 肺癌患者感染SARS-CoV-2的风险较对照高7倍以上。
  • 肺癌患者住院风险较对照高3倍以上,且并发症发生率高。
  • 估计病死率超过30%。
  • COVID-19疫苗对肺癌患者安全有效。
  • 部分肺癌患者对疫苗接种的抗体应答较差(原因未知)。

临床怎么用

  • 基于现有数据,肺癌患者应继续其癌症治疗疗程。
  • 基于现有数据,肺癌患者应接种SARS-CoV-2疫苗。
  • 部分肺癌患者疫苗接种抗体应答较差,该脆弱亚组似需紧急加强接种。
  • 需解决的知识空白包括:如何最好地保护肺癌患者免于发生COVID-19(含医疗照护与家庭环境管理)。

局限性

  • 部分肺癌患者对疫苗接种抗体应答较差的原因未知。
  • 关于疫苗接种的抗体应答幅度、质量、持续时间及固有与获得性细胞免疫对临床保护的作用等许多问题仍未解答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%. The reasons for the increased vulnerability are not known. In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management.COVID-19 vaccines are safe and effective in people with lung cancer. On the basis of the available data, patients with lung cancer should continue their course of cancer treatment and get vaccinated against the SARS-CoV-2 virus. For unknown reasons, some patients with lung cancer mount poor antibody responses to vaccination. Thus, boosting vaccination seems urgently indicated in this subgroup of vulnerable patients with lung cancer. Nevertheless, many unanswered questions regarding vaccination in this population remain, including the magnitude, quality, and duration of antibody response and the role of innate and acquired cellular immunities for clinical protection. Additional important knowledge gaps also remain, including the following: how can we best protect patients with lung cancer from developing COVID-19, including managing care in patient with lung cancer and the home environment of patients with lung cancer; are there clinical/treatment demographics and tumor molecular demographics that affect severity of COVID-19 disease in patients with lung cancer; does anticancer treatment affect antibody production and protection; does SARS-CoV-2 infection affect the development/progression of lung cancer; and are special measures and vaccine strategies needed for patients with lung cancer as viral variants of concern emerge.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Rolfo C, Meshulami N, Russo A, et al. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2021. PMID: 34774792. doi:10.1016/j.jtho.2021.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。